tremelimumab

AstraZeneca and MedImmune presented encouraging results from their novel combination-focused immuno-oncology portfolio at ASCO Annual Meeting 2015

LONDON, 2-6-2015 — /EuropaWire/ — AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results…

9 years ago

AstraZeneca’s global biologics research and development arm MedImmune completed its acquisition of US-based Amplimmune for $225M plus $275M based on predetermined milestones

London, United Kingdom, 10-10-2013 — /EuropaWire/ — AstraZeneca today announced that on 4 October MedImmune, its global biologics research and development arm,…

11 years ago